Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral Healthmeridian Spravato Coverage Prior Auth Policy | Ope…
    Ask Trek AI about this page
    CurrentmeridianPolicy MDN.CP.PMN.199

    Clinical Policy: Esketamine (Spravato)

    Customize your policy alerts

    Sign up for meridian Policy MDN.CP.PMN.199 alerts

    Get alerted when Policy MDN.CP.PMN.199 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Meridian Health Plan medical necessity and prior authorization criteria for esketamine (Spravato) for treatment-resistant depression and MDD with acute suicidal ideation/behavior for Illinois Medicaid line of business.

    Policy Summary
    Payermeridian
    PolicyEsketamine (Spravato) — coverage criteria for TRD and MDD with suicidality
    Policy CodePolicy MDN.CP.PMN.199
    Change TypeNo material changes
    Effective DateJul 1, 2025
    Last ReviewJun 2, 2025
    Next Review DateJun 2, 2025
    Key ActionSubmit documentation (office chart notes, lab results, or clinical information) demonstrating the member meets all approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18–64Age limit (TRD)
    PHQ-9 ≥15Baseline severity
    ≥2 failedPrior antidepressant trials
    56 / 84 mgDosing options

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    G2082,G2083,S0013
    HCPCS codes

    Coverage Criteria

    Initial Therapy — Treatment-Resistant Depression

    Covered when ALL of the following are met for Treatment-Resistant Depression (initial approval):

    TRD Initial: 1. Diagnosis of treatment-resistant depression (TRD).
    TRD Initial: 2. Prescribed by or in consultation with a psychiatrist.
    TRD Initial: 3. Age ≥ 18 and < 65 years.
    TRD Initial: 4. Documented baseline PHQ-9 score ≥ 15 within the previous 4 weeks.
    TRD Initial: 5. Failure of two antidepressants from at least two different classes at up to maximally indicated doses (but not less than commonly recognized minimum therapeutic doses), each used ≥ 8 weeks unless clinically significant adverse effects or contraindications exist (examples: SSRI, SNRI, TCA, bupropion, mirtazapine).
    TRD Initial: 6. Failure of two augmentation strategies (each used ≥ 4 weeks) unless clinically significant adverse effects or contraindications exist (examples: second-generation antipsychotic, lithium, thyroid hormone, buspirone).
    TRD Initial: 7. Currently stabilized on an oral antidepressant for at least 2 weeks that is not one of the previously failed agents, and Spravato will be used in combination with the oral antidepressant.
    TRD Initial: 8. Either: (a) no prior history of treatment with Spravato; or (b) documentation of prior positive response to Spravato defined as ≥ 50% reduction in PHQ-9 score.
    TRD Initial: 9. Dose during the 4-week induction phase does not exceed 168 mg per week.

    Approval duration: 6 months

    Initial Therapy — MDD with Suicidal Ideation or Behavior

    Covered when ALL of the following are met for Major Depressive Disorder with Suicidal Ideation or Behavior (initial approval):

    MDD with Suicidality Initial: 1. Diagnosis of major depressive disorder (MDD).
    MDD with Suicidality Initial: 2. Prescribed by or in consultation with a psychiatrist.
    MDD with Suicidality Initial: 3. Age ≥ 18 years.
    MDD with Suicidality Initial: 4. Spravato is prescribed in combination with initiation or optimization of an oral antidepressant therapy.
    MDD with Suicidality Initial:

    Continued Therapy

    Continued therapy coverage criteria:

    Continued Therapy — TRD: 1. Member currently receiving Spravato via Centene benefit or previously met initial approval criteria; or member is receiving medication and is in a state/product with continuity of care regulations.
    Continued Therapy — TRD: 2. Member is responding positively to therapy as evidenced by at least a 50% reduction in PHQ-9 score from baseline.
    Continued Therapy — TRD: 3. Spravato is being used in combination with an oral antidepressant.
    Continued Therapy — TRD: 4. If request is for a dose increase, the new dose does not exceed 84 mg (3 nasal spray devices) per week.

    Approval duration: 12 months

    Coverage criteria for esketamine (Spravato)

    Covered when ALL of the following are met

    Main coverage criteria: 1. Patient is enrolled in the Spravato REMS program and treatment is administered in a REMS-certified healthcare setting.
    Main coverage criteria: 2. Spravato is administered by direct observation of a healthcare provider and patients are monitored for at least 2 hours after each administration.
    Main coverage criteria: 3. Spravato is given in conjunction with an oral antidepressant for TRD (or per indication for MDD with acute suicidal ideation/behavior) and dosing follows the specified induction and maintenance regimens (56 mg or 84 mg per administration as indicated).
    Main coverage criteria: 4. Dosing limits are respected: induction phase weeks 1–4 twice weekly (Day 1 starting dose 56 mg, subsequent 56 mg or 84 mg); maintenance weeks 5–8 once weekly; week 9+ every 2 weeks or once weekly per regimen; maximum per-administration dose is 84 mg.

    Coverage for non‑FDA indications is not authorized unless the requested use is specifically addressed by this policy or the provider supplies sufficient clinical documentation supporting safety and efficacy in accordance with Meridian’s off‑label use guidance (see policy CP.PMN.53). Requests for off‑label uses should include pertinent literature or evidence and meet the same standards for medical necessity as FDA‑approved indications; otherwise the request may be denied.

    This policy’s covered indications include: Treatment‑Resistant Depression (TRD) and Major Depressive Disorder (MDD) with acute suicidal ideation or behavior when all indication‑specific criteria are met (see Initial Therapy sections). All approvals require documentation of baseline severity using validated scales (PHQ‑9, MADRS, or HAM‑D17) and the treatment plan submitted with prior authorization must demonstrate adherence to dosing, monitoring, and REMS program requirements.

    Requests for continuation of therapy for members who previously met initial approval criteria or who are continuing treatment under continuity‑of‑care provisions must demonstrate ongoing clinical benefit (for TRD this is defined as ≥50% reduction in PHQ‑9 from baseline) and continued concomitant use of an oral antidepressant as specified in the continued therapy criteria. Continued approvals also require documentation of REMS enrollment, adherence to maintenance dosing schedules, and monitoring.

    Spravato is not indicated for the treatment of bipolar depression and must not be used in patients with specified vascular or bleeding risks. Contraindications include aneurysmal vascular disease or arteriovenous malformation, a history of intracerebral hemorrhage, and hypersensitivity to esketamine, ketamine, or any excipient. These contraindications should be verified in the medical record prior to authorization.

    Spravato carries boxed warnings that require monitoring for sedation and dissociation with at least 2 hours of post‑administration observation, and warnings about the potential for abuse and misuse. The product is available only through the Spravato REMS program; lack of REMS enrollment for the patient, administering site, or dispensing pharmacy may result in denial or noncompliance.

    Additionally, requests for indications not addressed in this policy remain subject to denial unless the off‑label request is supported per Meridian’s off‑label policy (CP.PMN.53). Use in pediatric patients is not approved; Spravato is not indicated for pediatric use and antidepressants carry increased risk of suicidal thoughts in children and young adults.

    Spravato is not approved as an anesthetic agent. The safety and effectiveness of esketamine when used as an anesthetic have not been established, and such uses are outside the scope of this coverage policy and will be considered not medically necessary.

    Clinical trial data show limited evidence of benefit for geriatric patients with TRD aged 65–74. In the TRANSFORM‑3 study (ages 65–74) Spravato plus oral antidepressant did not achieve a statistically significant improvement versus placebo plus antidepressant on the primary efficacy endpoint (change in MADRS at Week 4). Safety outcomes in that trial were generally consistent with previous studies, but treatment‑emergent adverse events were frequent.

    Because of the TRANSFORM‑3 results, the policy requires standard indication criteria and evidence of clinical benefit for geriatric members and notes that utility in the 65–74 subgroup may be limited. Providers should document expected benefit and monitor closely for adverse events; REMS enrollment and the required post‑dose observation period remain mandatory for older adults as for all patients.

    For completeness, clinicians should recognize that Spravato’s dosing and monitoring requirements — induction/maintenance schedules (56 mg or 84 mg dosing options), dosing caps during induction, REMS‑certified administration setting, and ≥2 hour post‑dose monitoring — apply to geriatric patients in the same manner as younger adults and must be reflected in prior authorization documentation.

    Coding

    HCPCS CodesHCPCS
    G2082Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post administration observation
    G2083Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post administration observation
    S0013Esketamine, nasal spray, 1 mg
    PHQ-9 / MADRS / HAM-D thresholds
    PHQ-9 thresholdPHQ-9 ≥ 15 (baseline within previous 4 weeks)
    MADRS thresholdMADRS ≥ 20
    HAM-D (HAMD) thresholdHAMD ≥ 17
    Response definitionResponse defined as ≥ 50% reduction in PHQ-9 from baseline
    Maximum dose per administration
    Maximum single administration dose84 mg per administration (3 nasal spray devices)
    Maximum weekly induction cap (TRD)

    Provider Actions and Requirements

    Prior Authorization

    Prior authorization requirement

    Prior authorization is not required for members currently prescribed/taking Spravato when one of the following continuity conditions is met: member changed providers (including inpatient to outpatient), member changed insurance providers, or a prior authorization was previously approved and the new prescription only modifies dosage and/or frequency. For all other situations, prior authorization is required and initial approval criteria must be met.

    • PA not required if member changed providers (including inpatient to outpatient).
    • PA not required if member changed insurance providers.
    • PA not required if prior PA approved and new prescription only modifies dose or dosage frequency.
    Prior Authorization

    Prior authorization: HCPCS codes and REMS enrollment

    Include the applicable HCPCS codes and document REMS enrollment on the prior authorization. Use HCPCS G2082 for administrations up to 56 mg, G2083 for administrations greater than 56 mg, and S0013 for the product (Esketamine, nasal spray, 1 mg). Ensure dosing (56 mg or 84 mg options) and that the healthcare setting and patient are enrolled in the Spravato REMS are documented.

    Background

    Esketamine (Spravato) is a non‑competitive N‑methyl‑D‑aspartate (NMDA) receptor antagonist formulated as an intranasal spray. It is FDA‑approved for use in adults as an adjunct to an oral antidepressant for treatment‑resistant depression (TRD) and for adults with major depressive disorder with acute suicidal ideation or behavior, when administered in a REMS‑certified healthcare setting. Administration must be under direct healthcare professional supervision with monitoring for at least 2 hours after each dose, and Spravato is available only through the Spravato REMS program.

    Definitions

    TRD (as used in policy)
    Operational definitionTRD requires a diagnosis of treatment‑resistant depression with documented failure of ≥2 antidepressants from at least two different classes (each used ≥8 weeks) and failure of ≥2 augmentation therapies (each used ≥4 weeks)
    Concomitant therapy requirementSpravato must be administered in combination with an oral antidepressant (patient stabilized on oral antidepressant ≥2 weeks)
    Age and prior use notesIndication applies to adults; prior Spravato allowed if prior positive response documented (≥50% reduction in PHQ‑9) or no prior history of Spravato
    Spravato REMS
    Program requirementSpravato is available only through the Spravato REMS; healthcare settings and pharmacies must be certified in the REMS program
    Administration and dispensing

    Level of Care Criteria

    Treatment Modalities

    Visit Limits and Supply

    MDD with suicidality induction supply — up to 23 nasal spray devices
    Induction supply limitApproval duration 4 weeks — up to 23 nasal spray devices provided for MDD with suicidal ideation/behavior
    Per-device contentEach nasal spray device contains 28 mg of esketamine
    Dosing cap for suicidality indicationDose does not exceed 84 mg (3 devices) twice weekly
    Esketamine administration (coded with G2082/G2083) — frequency tied to induction/maintenance schedule
    Billing codes and observation periodEsketamine administration is coded with G2082 (up to 56 mg) or G2083 (greater than 56 mg); both include 2 hours post-administration observation
    Frequency tied to treatment phaseProvision frequency: twice weekly during induction; once weekly during early maintenance; every 2 weeks or once weekly during later maintenance
    Policy Summary
    Payermeridian
    PolicyEsketamine (Spravato) — coverage criteria for TRD and MDD with suicidality
    Policy CodePolicy MDN.CP.PMN.199
    Change TypeNo material changes
    Effective DateJul 1, 2025
    Last ReviewJun 2, 2025
    Next Review DateJun 2, 2025
    Key ActionSubmit documentation (office chart notes, lab results, or clinical information) demonstrating the member meets all approval criteria.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and RequirementsBackgroundDefinitionsLevel of Care CriteriaTreatment ModalitiesVisit Limits and Supply
    5. Member was recently (within the last 5 days) discharged from or is currently in acute/subacute inpatient care for suicidality.
    MDD with Suicidality Initial: 6. Either: (a) no prior history of treatment with Spravato; or (b) documentation of prior positive response to Spravato.
    MDD with Suicidality Initial: 7. Meets one of the following baseline severity thresholds: MADRS ≥ 20 OR HAMD ≥ 17 OR PHQ-9 ≥ 15.
    MDD with Suicidality Initial: 8. Dose does not exceed 84 mg (3 nasal spray devices) twice weekly.

    Approval duration: 4 weeks (up to 23 nasal spray devices)

    Continued Therapy — MDD with Suicidality: Re-authorization is not permitted for MDD with suicidal ideation or behavior; members must meet initial approval criteria for that indication.

    See Dosage and Administration section for schedule specifics.

    Does not exceed 168 mg per week during 4-week induction phase
    MDD with suicidality dosing capDose does not exceed 84 mg twice weekly (per authorization)
    • HCPCS: G2082 — up to 56 mg administration (includes 2-hour post-administration observation).
    • HCPCS: G2083 — greater than 56 mg administration (includes 2-hour post-administration observation).
    • HCPCS: S0013 — Esketamine, nasal spray, 1 mg.
    • Document Spravato REMS enrollment of the healthcare setting and patient.
    Step Therapy

    Required prior therapy

    For Treatment-Resistant Depression prior authorization requests must document failure of two antidepressants from at least two different classes each used for ≥8 weeks at therapeutic doses, and failure of two augmentation therapies each used ≥4 weeks unless contraindicated or not tolerated.

    • Antidepressant trials: ≥2 agents from different classes (e.g., SSRI, SNRI, TCA, bupropion, mirtazapine) used ≥8 weeks each.
    • Augmentation trials: ≥2 strategies (second-generation antipsychotic, lithium, thyroid hormone, buspirone) used ≥4 weeks each.
    Step Therapy

    Combination with oral antidepressant

    Spravato must be administered in conjunction with an oral antidepressant for TRD and MDD with suicidal ideation/behavior per the policy. Document concurrent oral antidepressant therapy at initiation and during ongoing therapy.

    • Induction and maintenance dosing are specified with Spravato given alongside an oral antidepressant.
    • For TRD, member must be stabilized on an oral antidepressant at least two weeks (not one previously failed).
    Documentation Required

    Documentation requirement

    Submit supporting clinical documentation with the prior authorization: office chart notes, lab results, or other clinical information that demonstrates the member meets all approval criteria.

    • Include records that verify diagnosis, prior therapy history, baseline rating scale scores, and REMS enrollment as applicable.
    Documentation Required

    Depression rating scales and response documentation

    Document baseline and follow-up depression rating scales and treatment response: baseline PHQ-9 (for TRD baseline must be ≥15 within 4 weeks), and as applicable MADRS or HAM-D17. For continued therapy, provide evidence of response such as ≥50% reduction in PHQ-9 from baseline.

    • Baseline PHQ-9 ≥15 within prior 4 weeks for TRD.
    • MADRS ≥20 or HAM-D17 ≥17 may be used for MDD with suicidality.
    • Continued therapy requires ≥50% reduction in PHQ-9 from baseline to show response.
    Note

    Non‑FDA indications — off‑label requests handling

    Requests for indications that are not FDA‑approved and are not addressed in this policy may be denied unless sufficient documentation of efficacy and safety is provided per the Off‑Label Use policy (CP.PMN.53) or other evidence of coverage documents. Include supportive literature or documentation when seeking coverage for non‑FDA indications.

    • Non‑FDA indications must have sufficient documentation per off‑label use policy CP.PMN.53 (Medicaid) or evidence of coverage documents.
    • If policy does not address the indication, provide efficacy and safety evidence to support the request.
    Denial Risk

    REMS and monitoring noncompliance — denial risk and requirements

    Failure to ensure REMS requirements or to monitor patients as required may result in denial or noncompliance. The healthcare setting and pharmacies must be REMS‑certified, patients must be enrolled in the Spravato REMS, Spravato must be administered under direct observation, and patients must be monitored for at least 2 hours after each administration.

    • Healthcare settings and dispensing pharmacies must be certified in the Spravato REMS.
    • Patients must be enrolled in the REMS and administered Spravato under direct observation.
    • Monitor patients for at least 2 hours post‑administration; lack of REMS compliance or monitoring may trigger denial.
    Spravato is only dispensed to REMS-certified healthcare settings and administered to patients enrolled in the REMS
    Post-dose monitoringPatients must be monitored by a healthcare provider for at least 2 hours after each administration
    Induction and Maintenance dosing
    Induction (Weeks 1–4) — TRDAdminister nasally twice per week; Day 1 starting dose 56 mg, subsequent doses 56 mg or 84 mg
    Maintenance (Weeks 5–8)Administer 56 mg or 84 mg nasally once weekly
    Maintenance (Week 9+)Administer 56 mg or 84 mg every 2 weeks or once weekly as clinically indicated
    Product codeProduct HCPCS S0013 = Esketamine, nasal spray, 1 mg (use in dose calculation and claims)